Kardigan launches $320M IPO to fund three late-stage cardio drugs as biotech listings hit a post-pandemic high.
Tassos Gianakakos, Kardigan CEO
June 11, 2026 09:32 AM EDT
Kardigan's $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO
Parabilis Medicines’ record-breaking IPO will be a tough act to follow, but a drug developer with three late-stage cardio medicines is up …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Cardiology biotech Kardigan filed for a Nasdaq IPO under ticker {$KARD}, joining a growing roster of clinical-stage drug…
Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical…
Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of…
Dollarama beats forecasts; Takeda's psoriasis drug shines; Xiaomi plans new EV
Cartesian’s $150M financing; Editas Medicine’s money moves
Odyssey Therapeutics raised $279 million in an upsized IPO priced at $18 a share, with the autoimmune disease biotech set to…
ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree
